Aristides Capital LLC Buys 8,000 Shares of BioNTech SE Sponsored ADR $BNTX

Aristides Capital LLC boosted its position in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 46.1% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 25,359 shares of the company’s stock after buying an additional 8,000 shares during the quarter. Aristides Capital LLC’s holdings in BioNTech were worth $2,501,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in the business. Mackenzie Financial Corp raised its stake in shares of BioNTech by 4.0% during the third quarter. Mackenzie Financial Corp now owns 4,290 shares of the company’s stock worth $418,000 after buying an additional 165 shares during the last quarter. Victory Capital Management Inc. grew its stake in shares of BioNTech by 97.0% during the third quarter. Victory Capital Management Inc. now owns 413,685 shares of the company’s stock worth $37,531,000 after purchasing an additional 203,700 shares during the period. APG Asset Management N.V. increased its holdings in BioNTech by 3.0% in the third quarter. APG Asset Management N.V. now owns 54,700 shares of the company’s stock valued at $5,395,000 after purchasing an additional 1,600 shares during the last quarter. Huntington National Bank boosted its holdings in BioNTech by 1,266.7% during the third quarter. Huntington National Bank now owns 410 shares of the company’s stock worth $40,000 after buying an additional 380 shares during the last quarter. Finally, Fox Run Management L.L.C. increased its stake in shares of BioNTech by 242.8% in the 3rd quarter. Fox Run Management L.L.C. now owns 9,750 shares of the company’s stock valued at $962,000 after acquiring an additional 6,906 shares during the last quarter. 15.52% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on BNTX shares. Morgan Stanley reduced their price target on shares of BioNTech from $134.00 to $125.00 and set an “overweight” rating on the stock in a research report on Tuesday. Canaccord Genuity Group reissued a “buy” rating and set a $171.00 price objective on shares of BioNTech in a research report on Wednesday. Weiss Ratings restated a “sell (d-)” rating on shares of BioNTech in a report on Friday, January 9th. Truist Financial set a $155.00 price objective on shares of BioNTech in a report on Tuesday. Finally, TD Cowen dropped their target price on BioNTech from $116.00 to $94.00 and set a “hold” rating on the stock in a report on Wednesday. Twelve analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $133.73.

BioNTech Stock Performance

NASDAQ BNTX opened at $90.10 on Friday. The company has a quick ratio of 7.02, a current ratio of 7.54 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $20.29 billion, a P/E ratio of -17.19 and a beta of 1.51. The firm has a 50-day moving average price of $106.54 and a two-hundred day moving average price of $102.66. BioNTech SE Sponsored ADR has a 12-month low of $79.52 and a 12-month high of $124.00.

Key Headlines Impacting BioNTech

Here are the key news stories impacting BioNTech this week:

• Positive Sentiment: Canaccord reiterated a “buy” rating and set a high $171 price target, signaling strong upside relative to the current level and supporting bullish investor thesis on long‑term mRNA opportunity. Canaccord reaffirms buy, $171 PT
• Positive Sentiment: Goldman Sachs reaffirmed its “buy” rating, providing another institutional vote of confidence that may stabilize sentiment among growth‑oriented holders. Goldman Sachs reaffirms buy
• Positive Sentiment: BioNTech and its co‑founders announced plans to pursue next‑generation mRNA innovations — a strategic signal that the company is investing in future product pipelines beyond COVID vaccines. Co‑founders pursue next‑gen mRNA
• Neutral Sentiment: Independent write‑ups are debating whether recent weakness makes BNTX a value play; the analysis highlights multi‑period share declines but leaves valuation conclusions to readers. Yahoo analysis on BNTX valuation
• Neutral Sentiment: Data feeds flagged a “large increase” in short interest, but the published figures are inconsistent (zeros/NaN and 0.0 days to cover), suggesting a likely reporting glitch rather than actionable short‑squeeze pressure.
• Neutral Sentiment: BMO trimmed its price target (to $128) but kept an “outperform” stance — a modest downgrade in optimism rather than a rout. BMO lowers PT to $128
• Negative Sentiment: Several outlets reported a steep share drop after an earnings miss and leadership changes (founder departures); that combination typically triggers near‑term selling and raises execution risk. Earnings miss & founder exodus — Blockonomi Earnings miss & leadership change — Tokenist
• Negative Sentiment: Multiple sell‑side revisions trimmed expectations: Citigroup lowered its PT to $130 (still a “buy”), TD Cowen cut to $94 and moved to “hold”, and Jefferies published more cautious forecasts — collectively cooling near‑term analyst enthusiasm. Citigroup cuts PT to $130 TD Cowen cuts to $94 Jefferies lowers expectations

About BioNTech

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.